Systemic Anti-Cancer Therapy Regimen Library
LEU CML - nilotinib
Treatment Overview
nilotinib 400: Accelerated, blast, or chronic phase CML resistant or intolerant to previous therapy, including imatinib - give continuously until disease progression or unacceptable toxicity.
nilotinib 300: Chronic phase treatment - give continuously until disease progression or unacceptable toxicity.
Supportive Care Factors
| Factor | Value |
|---|---|
| Emetogenicity: | Minimal to low |
| Tumour lysis syndrome prophylaxis: | Tumour lysis syndrome prophylaxis may be considered |
Cardiovascular risk factor and baseline QTc interval assessment are recommended – consult prescribing information for details.
Antiviral prophylaxis for hepatitis B virus: Guidance is limited to high-risk anti-cancer medicines. Clinicians will need to assess individual patient risk for other anti-cancer medicines.
References
Le Coutre P et al. "Nilotinib in accelerated phase chronic myelogenous leukemia patients with imatinib-resistance or –intolerance: update of a phase II study." J Clin Oncol 26:2008 (May 20 suppl; abstract 7050).
Novartis New Zealand Limited Tasigna New Zealand Datasheet 30 June 2020 https://www.medsafe.govt.nz/profs/datasheet/t/Tasignacap.pdf (Accessed 29 March 2022).
* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.
s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.